Pacer Advisors Inc. Has $6.81 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Pacer Advisors Inc. increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 79.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,345 shares of the company’s stock after buying an additional 9,860 shares during the period. Pacer Advisors Inc. owned 0.08% of Medpace worth $6,808,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Whittier Trust Co. increased its stake in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after purchasing an additional 35 shares during the last quarter. Assetmark Inc. boosted its holdings in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after purchasing an additional 43 shares in the last quarter. Proficio Capital Partners LLC increased its position in Medpace by 6.4% during the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company’s stock worth $237,000 after buying an additional 47 shares during the last quarter. Aviva PLC raised its holdings in Medpace by 2.7% during the fourth quarter. Aviva PLC now owns 1,833 shares of the company’s stock valued at $609,000 after buying an additional 48 shares in the last quarter. Finally, Park Avenue Securities LLC raised its holdings in Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company’s stock valued at $838,000 after buying an additional 48 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $447.49 on Monday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The stock has a market cap of $12.57 billion, a PE ratio of 33.27, a PEG ratio of 2.82 and a beta of 1.47. The firm has a 50-day simple moving average of $319.66 and a 200 day simple moving average of $320.58.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%. The company’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the company earned $2.75 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of a number of analyst reports. Cowen lowered Medpace from a “buy” rating to a “sell” rating in a report on Wednesday. Barclays upped their target price on Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 23rd. TD Cowen reiterated a “sell” rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and an average target price of $411.10.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.